Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | RARG | P13631 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981508 | 0.90 | RARB (0.67) | RARARARBRARGCNR2CNR1 | |
| SCHEMBL3678749 | 0.81 | RARB (0.78) | RARARARBRARGCYP19A1CYP11B1 | |
| SCHEMBL24252037 | 0.79 | MAPT (0.50) | CNR2MGLLKDM4ECYP3A4MAPT | |
| SCHEMBL9453202 | 0.79 | SMN1; SMN2 (0.53) | CNR2MGLLKDM4ETP53MAPT | |
| SCHEMBL8090921 | 0.78 | PLA2G4B (0.51) | RARARARBRARGCNR2CNR1 | |
| SCHEMBL9132226 | 0.78 | PLA2G4B (0.51) | RARARARBRARGCNR2CNR1 | |
| SCHEMBL9492347 | 0.77 | PLA2G4B (0.47) | RARARARBRARGCNR2MGLL | |
| SCHEMBL9485696 | 0.77 | CNR2 (0.48) | CNR2MGLLCNR1KDM4ETP53 | |
| SCHEMBL9485704 | 0.77 | MAPK1 (0.50) | CNR2CNR1KDM4ETP53CYP3A4 | |
| SCHEMBL9130548 | 0.77 | CNR2 (0.46) | CNR2MGLLCNR1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168241-A1 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168241-A1 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.